Company: AZN
Filing Date: 2025-08-18
Form Type: 6-K
Source: 0001654954-25-009748
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-08-18
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1. Director/PDMR Shareholding
18 August 2025

<div align='center'>**Transaction by Person Discharging Managerial Responsibilities**</div>

AstraZeneca PLC (the Company) announces that, on 15 August 2025, it was notified of a transaction in the Company's ordinary shares of $0.25 each (Ordinary Shares), by Aradhana Sarin, Executive Director and Chief Financial Officer, on 14 August 2025, as set out below.

| PDMR           | Position                                       | Nature of the transaction | Quantity | Price per Ordinary Share |
| Aradhana Sarin | Executive Director and Chief Financial Officer | Sale of Ordinary Shares   |     9563 | £115.117                 |

Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation